Skip to Main Content U.S. Department of Energy
Economic Development Office

Tri-Cities Tech Business Update

October 2009 Issue

IsoRay receives FDA clearance


IsoRay, Inc., based in Richland, Wash., has received clearance from the Food and Drug Administration that will allow the company to expand its market for its ProxcelanTM Cesium-131 brachytherapy seeds. The Cesium-131 seeds are currently used in the treatment of prostate cancer. The FDA clearance will allow IsoRay to broaden the scope of treatments to include lung, head, and neck tumors as well as tumors in other organs.

Contact at 520-240-4840.

PNNL's EDO

News & Events

Programs & Resources

Share This

Share This!

Additional Information

Subscribe

Current Issue

Back Issues